Osteoporosis drugs
Sep 23, 2025
Merck Wins FDA Approval for KEYTRUDA QLEX for Subcutaneous Use in Adults With Solid Tumors; Incyte Gains FDA Nod for OPZELURA Cream in Children Aged 2–11 With Atopic Dermatitis; Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome; MavriX Bio Secures FDA Fast Track for MVX-220 Gene Therapy in Angelman Syndrome; Biocon Biologics Gets FDA Approval for Denosumab Biosimilars BOSAYA and AUKELSO
FDA Approves Merck’s KEYTRUDA QLEX for Subcutaneous Use Across Multiple Solid Tumors Merck announced that the FDA has approved KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous administration in adults across most of KEYTRUDA’s approved solid tumor indications. Unlike the intravenous...
Read More...
Oct 21, 2019
Emerging drugs bring a positive shift in Global Osteoporosis Market
Osteoporosis is not RARE. As per the International Osteoporosis Foundation (IOF), Osteoporosis affects an estimated 75 million people in Europe, USA and Japan. Approximately 10 million Americans are living with Osteoporosis and around 44 Million are struggling due to low bone density. Osteoporosis is k...
Read More...
Apr 15, 2019
New Osteoporosis Drug promises to rebuild Bone
Osteoporosis is a bone disease that makes bones weak and brittle. Osteoporosis, as the word says itself “porous bones”. As we age, bone density decreases and even mild stress or a light fall can cause severe damage. If this happens excessively, the result is Osteoporosis. The older bones keep on degrading, and new ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
